QGQiagen QGEN · NYSE
$46.54 +0.89% (+$0.41)
- Market cap
- $9.59B
- Enterprise value
- $10.5B
- P/E
- 23.4x
- Forward P/E
- 19.1x
- PEG
- 0.1x
- P/S
- 4.6x
- P/FCF
- 21.4x
- EV/EBITDA
- 14.2x
- ROIC
- 8.9%
- Gross margin
- 61.8%
- Net margin
- 19.5%
- Dividend yield
- 0.75%
- Payout ratio
- 17.6%
- Net debt/EBITDA
- 1.2x
- Beta
- 0.61
- Free float
- 99.4%
About the company
Qiagen N.V. (QGEN) is a Dutch company specializing in providing innovative diagnostic tests and technologies in the field of molecular biology. With a broad portfolio of products and services including tests for genetic mutations, infectious disease diagnostics, and analytical tools for genetic material research, Qiagen is one of the leading providers of diagnostic solutions in the market. The company focuses on providing accurate, reliable, and fast diagnostic tests that assist physicians and researchers in identifying and treating diseases. Qiagen also invests in innovation and the development of new diagnostic technologies to continuously improve patient diagnosis and treatment. Qiagen N.V. (QGEN) shares could be suitable for investors looking to invest in biotechnology companies with a focus on molecular diagnostics and innovative research and development in the healthcare sector.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jon Pratt
Employees
5,500
Headquarters
Venlo
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number